Clinical Network Services And Biopharma Global Enter Cooperative Partnership

Clinical Network Services (CNS), an international clinical and regulatory service group and Biopharma Global, an Orphan Drug regulatory consultancy, operating as a US based, not for profit corporation, today announced they have signed a cooperative partnership agreement.

This partnership reflects a mutual commitment by CNS and Biopharma Global to provide a broad and a comprehensive suite of regulatory services to meet the increased demand from international markets seeking uniquely experienced regulatory capabilities.

Together, CNS and Biopharma Global offer high-level solutions to the global biotechnology industry through combining CNS’ intelligent global product development & regulatory affairs consultancy arm, BioDesk, with its Australian and New Zealand based early phase clinical services and Biopharma Global’s niche expertise in Orphan Drug Designations (ODDs) to offer an unparalleled suite of product development capabilities.

The Managing Director of CNS, Russell Neal, commented, “We are delighted to be collaboratively working with Biopharma Global and deepening our Orphan Drug expertise through their highly respected regulatory team. We consider this synergy key in providing more effective support for clients as they implement their program strategies and add greater value to their IP”.

James LaFlamme, CEO of BioPharma Global added, “The agreement with CNS provides another dimension to an already highly regarded regulatory team led by our Chief Science Officer Dr. Sandi Heibel and Key Board member and Senior Advisor Dr. Marlene Haffner, the former head of OOPD at the FDA. The partnership allows Biopharma Global to provide a total solution to our clients from concept through marketing approval on a global basis”

About Clinical Network Services

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *